Abstracts tagged "hyperuricemia and risk assessment"

Abstract Number: 1117 • 2017 ACR/ARHP Annual Meeting
the Absolute Risk of Clinically Diagnosed Gout By Serum Uric Acid Levels – Results from 30 Years Follow-up of the Malmö Preventive Project Cohort in Southern Sweden
Meliha C. Kapetanovic¹, Peter M Nilsson², Carl Turesson³, Martin Englund⁴, Nicola Dalbeth⁵, Lieke E.J.M. Scheepers⁶ and Lennart TH Jacobsson⁶, ¹Lund University, Skane University Hospital, Department of Rheumatology, Lund, Sweden, Lund, Sweden, ²Department of Clinical Sciences, Lund University, Skåne University Hospital Malmö, Sweden., Lund, Sweden, ³Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, ⁴Clinical Sciences Lund, Orthopedics, Clinical Epidemiology Unit, Lund University, Lund, Sweden, ⁵University of Auckland, Auckland, New Zealand, ⁶Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Hyperuricemia i.e. increased s-uric acid levels (s-UA), is established risk factor for clinical gout. Studies regarding the absolute and relative effect on population level…
Abstract Number: 1119 • 2017 ACR/ARHP Annual Meeting
Uncontrolled Gout Patients with Higher Heart Failure Hospitalization Rates in US
Robert Morlock¹, Pierre Chevalier², An-Chen Fu³ and Douglas C.A. Taylor³, ¹YourCareChoice, Ann Arbor, MI, ²IMS Health, Zaventem, Belgium, ³Ironwood Pharmaceuticals, Inc., Cambridge, MA
Background/Purpose: Gout is the most common form of inflammatory arthritis and is caused by elevated serum uric acid (sUA). Elevated sUA is associated with worsened…
Abstract Number: 2073 • 2017 ACR/ARHP Annual Meeting
Predictors for Clinically Diagnosed Gout – Results from 30 Years Follow-up of the Malmö Preventive Project Cohort in Southern Sweden
Meliha C. Kapetanovic¹, Peter M Nilsson², Carl Turesson³, Nicola Dalbeth⁴, Martin Englund⁵, Lieke E.J.M. Scheepers⁶ and Lennart TH Jacobsson⁶, ¹Lund University, Skane University Hospital, Department of Rheumatology, Lund, Sweden, Lund, Sweden, ²Department of Clinical Sciences, Lund University, Skåne University Hospital Malmö, Sweden., Lund, Sweden, ³Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, ⁴University of Auckland, Auckland, New Zealand, ⁵Clinical Sciences Lund, Orthopedics, Clinical Epidemiology Unit, Lund University, Lund, Sweden, ⁶Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Gout is the most common form of arthritis worldwide. Hyperuricemia is a crucial risk factor resulting in accumulation of uric acid (s-UA) crystals in…
Abstract Number: 1721 • 2013 ACR/ARHP Annual Meeting
A Prediction Tool for Incident Gout Among Those With Hyperuricemia
Liseth Siemons¹ and Eswar Krishnan², ¹Department of Psychology, Health & Technology, University of Twente, Enschede, Netherlands, ²Medicine, Stanford University, Palo Alto, CA
Background/Purpose: The most common form of inflammatory arthritis observed in men is gout, a condition characterized by hyperuricemia and deposition of uric acid crystals in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].